21 CFR Encyclopedia → 21 CFR 211.68(b)
21 CFR 211.68(b)
Drugs
87 Annual Form 483 Citations
21 CFR 211.68(b) — Computer control of master formula records
Plain-English Risk Theme: Personnel GMP Training, Gowning & Hygienic Practices · Official eCFR Text ↗
Official FDA Inspectional Observation Template
"Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel. Specifically, ***"
Plain-English Brand & QA Translation
Operators performing manufacturing or QA tasks without documented GMP/SOP training, or observed gowning/hygiene deviations in production rooms.
🚨 Why 15-Day Form 483 Responses Fail on 21 CFR 211.68(b):
FDA routinely rejects 15-day Form 483 responses for 21 CFR 211.68(b) when a facility merely states 'we revised our SOP and retrained personnel' without attaching: (1) the signed, effective-dated SOP, (2) photographic or batch-log proof of implementation, and (3) a retrospective impact assessment of all commercial lots manufactured over the prior 24 months within expiry.
✅ Standard 15-Day CAPA Remediation Blueprint:
- Immediate Containment (Days 1–3): Place affected raw materials or in-process lots on QA Hold and open formal CAPA under 21 CFR 211.68(b).
- Systemic Root-Cause & SOP Overhaul (Days 4–10): Maintain role-based SOP training matrices signed prior to independent floor assignment and annual cGMP refresher assessments.
- Retrospective Lot Review & Effectiveness Check (Days 11–15): Test retention samples of distributed lots and schedule a 30/60/90-day QA audit to prove sustained compliance.
Copy-Paste Compliant SOP Clause Template (21 CFR 211.68(b))
FREE AUDIT-READY BOILERPLATESTANDARD OPERATING PROCEDURE — COMPLIANCE CLAUSE 21 CFR 211.68(b) 1. PURPOSE: Establish mandatory cGMP controls satisfying 21 CFR 211.68(b) (Computer control of master formula records). 2. REQUIREMENT: Maintain role-based SOP training matrices signed prior to independent floor assignment and annual cGMP refresher assessments. 3. QA VERIFICATION & SIGN-OFF: Dual independent verification by Production and Quality Assurance Unit (QAU) is required prior to batch release. Any deviation or Out-of-Specification (OOS) result triggers a formal CAPA investigation within 24 hours.
FDA Investigators Who Frequently Cite 21 CFR 211.68(b)
Published Form 483s Citing 21 CFR 211.68(b)
Right Value Drug Stores LLC
Issued 2026-09-08
Read 483 Breakdown →
TAILSTORM HEALTH INC
Issued 2026-08-28
Read 483 Breakdown →
BPI Labs, LLC
Issued 2026-04-17
Read 483 Breakdown →
Central Alabama Veterans Health Care System
Issued 2026-04-16
Read 483 Breakdown →
Wells Pharma of Houston LLC
Issued 2026-04-13
Read 483 Breakdown →
Fujifilm Diosynth Biotechnologies USA Inc.
Issued 2026-03-27
Read 483 Breakdown →
Cerovene Inc.
Issued 2026-03-23
Read 483 Breakdown →